Showing 42 articles tagged 'Drugs access':

Hormone therapy shortage should only last a few months says drugs industry body

25 Jan 2018

After we investigated complaints from men unable to get hold of the off-patent prostate cancer drug, bicalutamide, the British Generic Manufacturers' Association has told us problems with supply shouldn't last long.

Behind the scenes of drug approvals: what we’re doing to get you access to the best possible treatments

9 Jan 2018

BLOG: BLOG: When a successful clinical trial of a new treatment is reported, what happens next? Even the most exciting new methods still have a long way to go before doctors can prescribe them. Behind the scenes, we work to try and make sure these treatments get to the men who need them. This month, Policy Manager, Tim Windle, is in the thick of it in a bid to get a combination therapy for advanced disease approved.

Study finds early docetaxel and abiraterone equally effective

8 Sep 2017

Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.

29,000 voices backed our petition, but the NHS is still going ahead with their proposed plans

31 Mar 2017

We handed in our ‘Don’t delay funding for vital new drugs and treatments’ petition to NHS England, to urge them to reconsider plans for a new spending cap on treatments. We received an incredible 29,006 signatures, but unfortunately the outcome wasn’t what we hoped for.

‘Unacceptable’ NHS cost cap threatens next generation of prostate cancer treatments

14 Mar 2017

Thousands of men could be delayed or denied life-saving new drugs under plans to cap spending by NHS England, prompting "serious concern" and an online petition from leading health and care charities.

Cabazitaxel decision in Scotland finally ends UK variation in NHS drug access

12 Dec 2016

Today's Scottish green light for the chemotherapy drug means the same key treatments for advanced prostate cancer are now routinely available to eligible men in all the home nations.

Radium-223 now available before chemotherapy for men in England and Wales following NICE reappraisal

2 Sep 2016

Men living in the two home nations with prostate cancer that's spread to the bones will now be able to access the life-enhancing treatment on the NHS if they're unable to have chemotherapy, thanks to reversal of a decision in 2015.

Campaign cuts through red tape to get men with prostate cancer in Wales access to benefits of earlier chemotherapy

15 Aug 2016

Eligible men in Wales with newly diagnosed advanced prostate cancer will now be offered earlier access to docetaxel chemotherapy alongside hormone therapy. Combining these treatments has been shown to offer these men the possibility of an extra fifteen months of life on average.

Cancer Drugs Fund reforms aim to give patients faster access to new treatments but underlying problems remain

29 Jul 2016

After months of consultation and negotiation, the proposed changes to the Cancer Drugs Fund come into effect. But do they go far enough for men with prostate cancer?

Degarelix approved for men in England whose cancer has spread to the spine

1 Jul 2016

Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.